ZIMV vs. TRDA, STTK, BTMD, BMEA, PLSE, CRBP, VYGR, HROW, LXRX, and SKIN
Should you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include Entrada Therapeutics (TRDA), Shattuck Labs (STTK), biote (BTMD), Biomea Fusion (BMEA), Pulse Biosciences (PLSE), Corbus Pharmaceuticals (CRBP), Voyager Therapeutics (VYGR), Harrow Health (HROW), Lexicon Pharmaceuticals (LXRX), and Beauty Health (SKIN). These companies are all part of the "medical" sector.
Entrada Therapeutics (NASDAQ:TRDA) and ZimVie (NASDAQ:ZIMV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.
Entrada Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 72.98%. ZimVie has a consensus target price of $16.00, indicating a potential upside of 4.51%. Given ZimVie's stronger consensus rating and higher probable upside, research analysts clearly believe Entrada Therapeutics is more favorable than ZimVie.
86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 95.6% of ZimVie shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 3.0% of ZimVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Entrada Therapeutics has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500. Comparatively, ZimVie has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500.
In the previous week, ZimVie had 2 more articles in the media than Entrada Therapeutics. MarketBeat recorded 2 mentions for ZimVie and 0 mentions for Entrada Therapeutics. ZimVie's average media sentiment score of 0.00 equaled Entrada Therapeutics'average media sentiment score.
Entrada Therapeutics has a net margin of -5.18% compared to Entrada Therapeutics' net margin of -51.33%. Entrada Therapeutics' return on equity of 2.44% beat ZimVie's return on equity.
Entrada Therapeutics has higher earnings, but lower revenue than ZimVie. Entrada Therapeutics is trading at a lower price-to-earnings ratio than ZimVie, indicating that it is currently the more affordable of the two stocks.
Entrada Therapeutics received 11 more outperform votes than ZimVie when rated by MarketBeat users. Likewise, 73.33% of users gave Entrada Therapeutics an outperform vote while only 0.00% of users gave ZimVie an outperform vote.
Summary
Entrada Therapeutics beats ZimVie on 10 of the 17 factors compared between the two stocks.
Get ZimVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
